⁹⁹mTC-sestamibi breast imaging: Current status, new ideas and future perspectives

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceuticals

Background:

• Breast cancer management relies on accurate staging and prediction of metastasis.
• ⁹⁹mTc-sestamibi is a radiotracer used in nuclear medicine for imaging.
• Breast Specific Gamma Imaging (BSGI) utilizes gamma rays for specialized breast imaging.

Purpose of the Study:

• To review recent innovations in BSGI using ⁹⁹mTc-sestamibi for breast cancer.
• To explore the role of BSGI in predicting metastatic disease.
• To investigate BSGI's potential in identifying bone metastasis risk.

Main Methods:

• Review of recent advancements in BSGI instrumentation and software.
• Analysis of biological mechanisms of ⁹⁹mTc-sestamibi uptake in breast cancer.
• Evaluation of BSGI as a predictive marker for metastatic breast cancer.

Main Results:

• Innovations in BSGI technology and software have been implemented.
• Understanding of ⁹⁹mTc-sestamibi uptake mechanisms in breast cancer cells is advancing.
• BSGI shows potential as a predictive marker for metastatic disease, including bone metastases.

Conclusions:

• BSGI with ⁹⁹mTc-sestamibi represents a significant innovation in breast cancer patient management.
• The technique may help identify patients at higher risk for bone metastasis.
• Further research is warranted to fully establish BSGI's role in clinical practice.